Table of Contents

State/Territory Name: West Virginia

State Plan Amendment (SPA) #: 22-0015

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



March 24, 2023

Cynthia Beane, MSW, LCSW Commissioner Bureau for Medical Services 350 Capitol Street, Room 251 Charleston, WV 25301-3706

Re: West Virginia State Plan Amendment (SPA) 22-0015

Dear Commissioner Beane:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 22-0015. This amendment proposes to provide assurances that West Virginia covers and reimburses COVID-19 vaccine administration, testing, and treatment as required by Section 9811 of the American Rescue Plan Act of 2021.

Pursuant to section 1135(b)(5) of the Social Security Act (Act), for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

The State of West Virginia also requested a waiver to modify the public notice requirements applicable to the SPA submission process. Pursuant to section 1135(b)(5) of the Act, CMS is modifying public notice requirements applicable to the SPA submission process. Public notice for SPAs is required under 42 C.F.R. §447.205 for changes in statewide methods and standards for setting Medicaid payment rates, 42 C.F.R. §447.57 for changes to premiums and cost sharing, and 42 C.F.R. §440.386 for changes to Alternative Benefit Plans (ABPs). Pursuant to section 1135(b)(5) of the Act, CMS is approving the state's request to modify these notice requirements otherwise applicable to SPA submissions.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations. This letter is to inform you that West Virginia's Medicaid SPA Transmittal Number 22-0015 is approved effective March 11, 2021.

Page 2 – Commissioner Cynthia Beane

If you have any questions, please contact Dan Belnap at (215) 861-4273 or via email at Dan.Belnap@cms.hhs.gov.

Sincerely,

Alissa M.
Deboy -S
Deboy -S
Date: 2023.03 24
09:18:22 -04'00'

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

Enclosures

CENTERS FOR MEDICARE & MEDICAID SERVICES	-
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER 2. STATE 2 2 0 0 1 5 West Virginia
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)
TO: REGIONAL ADMINISTRATOR CENTERS FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE March 11, 2021
5. TYPE OF PLAN MATERIAL (Check One)	
☐ NEW STATE PLAN ☐ AMENDMENT TO BE CONS	
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME	NDMENT (Separate transmittal for each amendment)
 FEDERAL STATUTE/REGULATION CITATION Section 1905(a)(4)(E), Section 1905(a)(4)(F), and Section 1135(b)(5) of Social Security Act 	7. FEDERAL BUDGET IMPACT the a. FFY 2023
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION
Attachment 7.7-A, pages 1-3; Attachment 7.7-B, pages 1-3; Attachment 7.7-C, pages 1-3. 1-4	OR ATTACHMENT (If Applicable) N/A, new
10. SUBJECT OF AMENDMENT	
This SPA provides mandatory coverage for COVID-19 vaccines and treatment including specialized equipment and therapies during the begins one year after the last day of the public health emergency p	e period through the last day of the first calendar quarter that
11. GOVERNOR'S REVIEW (Check One)	
■ GOVERNOR'S OFFICE REPORTED NO COMMENT■ COMMENTS OF GOVERNOR'S OFFICE ENCLOSED■ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED
Count in Donne MCNA/ I CCNA/ Digitally signed by: Cynthia Beane, MSW, LCSW	16. RETURN TO Bureau for Medical Services
13. TYPED NAME	350 Capitol Street Room 251
	Charleston West Virginia 25301
14. TITLE Commissioner, Bureau for Medical Services	
15. DATE SUBMITTED 12/30/22 12/29/22	
FOR REGIONAL O	FFICE USE ONLY
17. DATE RECEIVED December 29, 2023	18. DATE APPROVED March 24, 2023
PLAN APPROVED - OI	NE COPY ATTACHED
19. EFFECTIVE DATE OF APPROVED MATERIAL March 11, 2021	20. SIGNATURE OF REGIONALAPISSAIAN. Deboy -S Date: 2023.03.24 09:18:41-04'00'
21. TYPED NAME	22. TITLE
Alissa Mooney DeBoy, on Behalf of Anne Marie Costello	Deputy Director, Center for Medicaid and CHIP Services
23. REMARKS	
Boxes 8 and 15: State authorized pen and ink chang	e on 03/16/2023

Attachment 7.7-A

Page 1

Vaccine and Vaccine Administration at Section 1905(a)(4)(E) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage

X The state assures coverage of COVID-19 vaccines and administration of the vaccines. ¹
X The state assures that such coverage:
 Is provided to all eligibility groups covered by the state, including the optional Individuals Eligible for Family Planning Services, Individuals with Tuberculosis, and COVID-19 groups if applicable, with the exception of the Medicare Savings Program groups and the COBRA Continuation Coverage group for which medical assistance consists only of payment of premiums; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(H) and section 1916A(b)(3)(B)(xii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
X Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing or similar charge, pursuant to section 1937(b)(8)(A) of the Act.
X The state provides coverage for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to §§1902(a)(11), 1902(a)(43), and 1905(hh) of the Act.
X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration, with respect to the providers that are considered qualified to prescribe, dispense, administer, deliver and/or distribute COVID-19 vaccines.
Additional Information (Optional):

¹ The vaccine will be claimed under this benefit once the federal government discontinues purchasing the vaccine.

Attachment 7.7-A

Page 2

Reimbursement

 \underline{X} The state assures that the state plan has established rates for COVID-19 vaccines and the administration of the vaccines for all qualified providers pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.

List Medicaid state plan references to payment methodologies that describe the rates for COVID-19 vaccines and their administration for each applicable Medicaid benefit:

Page 5, item 6d3 of Attachment 4.19-B in the state plan includes pharmacy reimbursement for vaccines, specifying that pharmacy reimbursement will be based on the appropriate NDC code at the current pharmacy reimbursement rate for covered drugs. If the vaccine is free, only an administration fee will be reimbursed.

SPA 21-0005 states the State will reimburse vaccine administration of COVID-19 vaccines based on the Medicare prevailing rate, excluding geographical adjustments.

\underline{X} The state is establishing rates for COVID-19 vaccines and the administration of the vaccines pursuant to sections 1905(a)(4)(E) and 1902(a)(30)(A) of the Act.
 X The state's rates for COVID-19 vaccines and the administration of the vaccines are consistent with Medicare rates for COVID-19 vaccines and the administration of the vaccines, including any future Medicare updates at the: X Medicare national average, OR Associated geographically adjusted rate.
The state is establishing a state specific fee schedule for COVID-19 vaccines and the administration of the vaccines pursuant to sections $1905(a)(4)(E)$ and $1902(a)(30)(A)$ of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location:
X The state's fee schedule is the same for all governmental and private providers.

Attachment 7.7-A

Page 3

Page 5
The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:
The payment methodologies for COVID-19 vaccines and the administration of the vaccines for providers listed above are described below:
X The state is establishing rates for any medically necessary COVID-19 vaccine inseling for children under the age of 21 pursuant to sections 1905(a)(4)(E), 1905(r)(1)(B)(v) I 1902(a)(30)(A) of the Act.
The state's rate is as follows and the state's fee schedule is published in the following
COVID-19 vaccine counseling rate will be the same as the counseling rate for other vaccines. ee schedule for these rates can be accessed at https://dhhr.wv.gov/bms/FEES/Pages/WV-caid-Physician's-RBRVS-Fee-Schedules.aspx

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

COVID-19 Testing at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage

X The states assures coverage of COVID-19 testing consistent with the Centers for Disease Control and Prevention (CDC) definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

X The state assures that such coverage:

- Includes all types of FDA authorized COVID-19 tests;
- 2. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 3. Is provided to the optional COVID-19 group if applicable; and
- 4. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

Please describe any limits on amount, duration or scope of COVID-19 testing consistent with 42 CFR 440.230(b).

WV Medicaid will cover one (1) over the counter (OTC) test kit per member, per week; each test kit has two (2) tests within.

X Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

 \underline{X} The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

Additional Information (Optional):

Should a member have a medical need for additional COVID-19 tests, an override of the limit can occur with prior approval.

Reimbursement

X The state assures that it has established state plan rates for COVID-19 testing consistent with the CDC definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 testing for each applicable Medicaid benefit:

Attachment 4.19-B Page 2d and Page 2g of the WV State Plan includes Laboratory Services benefits, under the Payments for Medical and Remedial Care Services section.

Payment shall be the lesser of 90% of the current Medicare established fee or the provider's usual and customary fee. The BMS Clinical Laboratory Fee Schedule is published at https://dhhr.wv.gov/bms/FEES/Pages/Clinical-Diagnostic-Lab-Fee-Schedules.aspx

The Bureau for Medical Services fee schedule rate is updated on January 1 of each year and is effective for services provided on or after that date.

The state is establishing rates for COVID-19 testing pursuant to pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.
1303(a)(4)(1) and 1302(a)(30)(A) of the Act.
The state's rates for COVID-19 testing are consistent with Medicare rates for
testing, including any future Medicare updates at the:
Medicare national average, OR
Associated geographically adjusted rate.
The state is establishing a state specific fee schedule for COVID-19 testing pursuant
to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location:
The state's fee schedule is the same for all governmental and private providers.

Attachment 7.7-B

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

Attachment 7.7-C

Page 1

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and Prevention of COVID

X The states assures coverage of COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

X The state assures that such coverage:

- 1. Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
- Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
- 3. Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19;
- 4. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 5. Is provided to the optional COVID-19 group, if applicable; and
- 6. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

X Applies to the state's approved Alternative Benefit Plans, without any deduction
cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

authorizations, including all of the amendments to the declaration. al Information (Optional):

X The state assures compliance with the HHS COVID-19 PREP Act declarations and

TN: <u>22-0015</u> Approval Date: <u>March 24, 2023</u>

Attachment 7.7-C

Page 2

Coverage for a Condition that May Seriously Complicate the Treatment of COVID

X The states assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.

- X The state assures that such coverage:
 - 1. Includes items and services, including drugs, that were covered by the state as of March 11, 2021;
 - Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;
 - 3. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
 - 4. Is provided to the optional COVID-19 group, if applicable; and
 - 5. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
 - X Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
- X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

F	Additional Information (Optional):	

Reimbursement

X The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

TN: <u>22-0015</u> Approval Date: <u>March 24, 2023</u>

Attachment 4.19-B Page 1 addresses Outpatient Hospital Services; reimbursement is based on a fee for service and may not exceed the amount established for any qualified provider for the same service. Other services specific to hospitals may not exceed the established Medicare upper limits based on reasonable cost.

Pages 2, 2a and 2b address Federally Qualified Health Center and Rural Health Center payment methodology; all Federally Qualified Health Centers and Rural Health Clinics are reimbursed on a prospective payment system. Covered Core Services are discussed on page 2a, include Physician services specified in 42 CFR 405.2412 as well as nurse practitioner or physician assistant services specified in 42 CFR 405.2414. Page 2d specifies that where a center/clinic furnishes services through a managed care organization, BMS will make a supplemental payment to the extent required by the Act.

Pages 3a and 3aa address payment methodology for Physicians' Services, while Page 3b discusses supplemental payments for certain Physician Services.

Pages 5 and 14 discuss payment methodology for different provider specialties for Nurse Practitioner services. Page 6 discusses payment for services provided by established clinics; payments are not to exceed that allowed for the services when provided by other qualified providers.

Page 7 includes payments for physical and occupational therapy. Pages 8 and 9 include payment methodologies for prescribed drugs. Page 13 discusses payment for respirator care services.

TN: <u>22-0015</u> Approval Date: <u>March 24, 2023</u>

The state's rates or fee providers.	schedule is the same for all governmental and private
The below listed prov	iders are paid differently from the above rate schedule
	s for COVID-19 vaccines and the administration of the er the benefit payment methodology applicable to the
provider type:	o 20 pa,

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN: <u>22-0015</u> Approval Date: <u>March 24, 2023</u>